Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an unmet need for broad-spectrum mAb treatments for COVID-19 that are more resistant to antigenically drifted SARS-CoV-2 variants...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wenjuan Du, Rick Janssens, Anna Z. Mykytyn, Wentao Li, Dubravka Drabek, Rien van Haperen, Marianthi Chatziandreou, Melanie Rissmann, Joline van der Lee, Melissa van Dortmondt, Itziar Serna Martin, Frank J. M. van Kuppeveld, Daniel L. Hurdiss, Bart L. Haagmans, Frank Grosveld, Berend-Jan Bosch
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-02-01
coleção:	Frontiers in Immunology
Assuntos:	heavy-chain-only antibody avidity SARS-CoV-2 antibody-mediated neutralization neutralization escape
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1111385/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!